通过电机模拟评估omecamtiv mecarbil在心力衰竭中的有效性
Maria Teresa Mora1, Ilse van Herck2, Cécile Daversin-Catty2
1Centro de Investigación e Innovación en Bioingeniería, Universitat Politècnica de València, Valencia, Spain.
The Journal of physiology
|August 20, 2025
概括
计算机模拟显示omecamtiv mecarbil可以改善心力衰竭的收缩性,但在高剂量或心率下,功能可能会恶化. 这项研究有助于了解心力衰竭治疗的药物机制.
科学领域:
- 心脏病学
- 计算生物学
- 药理学
背景情况:
- 心力衰竭 (HF) 是一种主要的心脏病理,涉及心肌功能障碍.
- 目前对HF的药物治疗需要改进,推动寻找新化合物的研究.
- 早期药物开发是昂贵的;计算机模拟提供了一种加速安全性和有效性评估的方法.
研究的目的:
- 通过计算机模拟,研究类药物omecamtiv mecarbil对心脏组织的电机效应.
- 在实验数据的基础上开发omecamtiv mecarbil的度依赖数值模型.
- 评估药物对心力衰竭的影响,降低射率 (HFrEF) 条件.
主要方法:
- 一个人类细胞电机模型被用来创建omecamtiv mecarbil的数值模型.
- 该模型在心室板上实施,以模拟心肌组织水平的影响.
- 模拟重现了HFrEF条件以评估药物的有效性和安全性.
主要成果:
- 在衰竭的肌细胞中,Omecamtiv mecarbil 纠正了抑制的活性,使缩恢复到健康水平.
- 观察到对收缩时间和透气功能的不良影响,可能会损害心脏的能力.
- 高刺激频率 (2 Hz) 和药物过量剂量 (> 0. 8 μm) 显著减少了部分缩短,并导致功能损失.
结论:
- 机电模拟提供了omecamtiv mecarbil的作用机制的洞察力.
- 这项研究强调了omecamtiv mecarbil的潜在风险,特别是在高剂量和心率下.
- 这种计算方法可以指导未来对心力衰竭药物开发的研究.
相关概念视频
01:30Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:29Heart Failure II: Pathophysiology
38
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
38
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505